Skip to content
Study details
Enrolling now

Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity

Jessie L. Alexander
NCT IDNCT06909110ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1/2

Target enrollment

25

Study length

about 6.7 years

Ages

0.0833333333333333–65

Locations

3 sites in CA

What this study is about

This trial is testing if giving patients specific T cells that fight viruses like adenovirus, cytomegalovirus, and Epstein-Barr virus can help them. The goal is to see if these T cells can improve the immune system's ability to fight off these infections in people who have weakened immunity due to previous transplants or other medical reasons.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive Adenovirus Specific T- Lymphocytes
  • 2.Receive Cytomegalovirus Specific T-Lymphocytes
  • 3.Receive Epstein-Barr Virus Specific T-Lymphocytes

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: CTCAE Grade 4/5 Adverse Events

Secondary: Viral load by Polymerase Chain Reaction (PCR), Viral load from Bronchoalveolar lavage (BAL), Viral load from Respiratory Viral Panel (RVP), Viral load from Stool, Viral load from Urine, Viral load from fluid/tissue